OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)

Article	Citations
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	43
Clots in unusual places: lots of stress, limited data, critical decisions	40
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	34
Acute GVHD: think before you treat	27
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	26
Optimal approach to T-cell ALL	26
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy	24
The dos, don'ts, and nuances of thrombophilia testing	23
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	22
Controversies in the management of early-stage Hodgkin lymphoma	22
Mastocytosis demystified	22
Diagnosis and therapeutic decision-making for the neutropenic patient	21
Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia	21
Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML	20
Inpatient recognition and management of HLH	20
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients	20
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	18
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	18
Lifelong TKI therapy: how to manage cardiovascular and other risks	17
What factors guide treatment selection in mycosis fungoides and Sezary syndrome?	17
AL amyloidosis: untangling new therapies	17
Dual-targeted regimens for the frontline treatment of CLL	17
Relapsed ALL: CAR T vs transplant vs novel therapies	16
Diagnostic pitfalls and conundrums in type 1 von Willebrand disease	16
Labor and delivery: DIC, HELLP, preeclampsia	16

Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	16
Bispecific antibody therapies	15
Cytoreduction for ET and PV: who, what, when, and how?	15
Provoked vs minimally provoked vs unprovoked VTE: does it matter?	15
How do we optimally utilize factor concentrates in persons with hemophilia?	14
Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?	13
Thrombocytopenia in pregnancy	13
What have we learned about the patient's experience of von Willebrand disease? A focus on women	13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	13
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies	13
Novel immunotherapies in the treatment of AML: is there hope?	13
Management of Fanconi anemia beyond childhood	12
Modern management of Fanconi anemia	12
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	12
Biology of follicular lymphoma: insights and windows of clinical opportunity	12
Dyskeratosis congenita and telomere biology disorders	12
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	11
Gene therapy for hemophilia	11
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	11
Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? Hematology Am Soc Hematol Educ Program. 2021;2021:521-528.	11
Recognizing, defining, and managing CAR-T hematologic toxicities	11
Neurological manifestations of MGUS	10
Mutations and MRD: clinical implications of clonal ontogeny	10
Novel conditioning and prophylaxis regimens for relapse prevention	10
The POD24 challenge: where do we go from here for early progressors?	10
Risk-stratification in frontline CLL therapy: standard of care	10
Your chemo is no good here: management of high-risk MCL	10
New definitions for antiphospholipid syndrome: ready for clinical use?	10
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	10
On the horizon: upcoming new agents for the management of ITP	10
Treatment of VTE in the thrombocytopenic cancer patient	10
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	10
What makes a pediatric or young adult patient an appropriate transplant candidate?	9
Anticoagulation at the end of life: whether, when, and how to treat	9
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	9
Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation	9
Modified T cells as therapeutic agents	9
Novel platelet products including cold-stored platelets	9
Pegylated interferon: the who, why, and how	9
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	8
Using disease-modifying therapies in sickle cell disease	8
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	8
Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy	8
Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?	8
Platelet components and bacterial contamination: hospital perspective 2022	8
Options at the time of relapse after anti-BCMA therapy	8
Novel approaches to acute graft-versus-host disease prevention	7
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	7
Passive immune therapies: another tool against COVID-19	7
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	7

Pyruvate kinase activators for treatment of pyruvate kinase deficiency	7
Amyloid consults do not have to be vexing	7
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma	7
How to avoid early mortality in acute promyelocytic leukemia	7
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	7
Heparin-induced thrombocytopenia and cardiovascular surgery	7
Long-term health outcomes following curative therapies for sickle cell disease	7
T-cell lymphopenia in frequent volunteer platelet donors	7
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	7
Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy	7
Upfront therapy: the case for continuous treatment	7
Identifying and treating iron deficiency anemia in pregnancy	7
Next-generation therapy for lower-risk MDS	7
The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure	7
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	7
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	6
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	6
Have we reached a molecular era in myelodysplastic syndromes?	6
Clinical manifestations of telomere biology disorders in adults	6
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	6
Targeted medical therapies for vascular anomalies	6
Has PD-1 blockade changed the standard of care for cHL?	6
Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia	6
Evidence-based management of pregnant women with sickle cell disease in high-income countries	6
Cold AIHA and the best treatment strategies	6
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	6
Challenges in hospice and end-of-life care in the transfusion-dependent patient	6
In pursuit of a functional cure for follicular lymphoma	6
Molecular prognostication in Ph-negative MPNs in 2022	6
Multiple myeloma: a paradigm for blending community and academic care	6
Williams KM. Noninfectious complications of hematopoietic cell transplantation. Hematology Am Soc Hematol Educ Program. 2021;2021:578-586.	6
Givosiran: a targeted treatment for acute intermittent porphyria	6
What is the ideal approach—doublet, triplet, or quadruplet(s)?	6